Gilead Sciences, INC Form 4 insider transactions

Gilead Sciences' EVP, Corporate Affairs & General Counsel, Deborah H. Telman, reported the vesting of Restricted Stock Units and a subsequent sale of shares to cover tax obligations.

Gilead Sciences, Inc.'s Chief Commercial Officer, Johanna Mercier, reported the vesting of restricted stock units and a subsequent sale of shares for tax withholding purposes.

Gilead Sciences, Inc. CEO and Chairman Daniel P. O'Day reported the acquisition of common stock through restricted stock unit conversion and a subsequent disposition for tax withholding purposes.

Gilead Sciences, Inc.'s Chief Financial Officer, Andrew D. Dickinson, reported the acquisition of common stock through the vesting of restricted stock units and the subsequent disposition of shares for tax withholding purposes.

Gilead Sciences, Inc., a 10% owner and director of Xilio Therapeutics, Inc., has acquired over 13 million units of prefunded and multi-series warrants, signaling a substantial investment in the biotechnology firm.

Gilead Sciences Chairman and CEO Daniel Patrick O'Day sold a total of 10,000 shares of common stock on May 30, 2025, through a pre-arranged Rule 10b5-1 trading plan.

Gilead Sciences' Chief Commercial Officer, Johanna Mercier, executed a series of transactions on May 22, 2025, involving the exercise of stock options and subsequent sale of common stock, all conducted under a pre-established Rule 10b5-1 trading plan.

Gilead Sciences' Chief Financial Officer, Andrew Dickinson, sold 2,500 shares of common stock at a price of $99.82 per share on May 15, 2025, according to a Form 4 filing with the SEC.

Director Sandra Horning reports the acquisition of stock options and restricted stock units (RSUs) in Gilead Sciences, Inc.

Director Harish Manwani reports acquisition of restricted stock units and stock options, along with disposition of common stock.

Director Kelly A. Kramer reports acquisition of stock options and restricted stock units in Gilead Sciences, Inc.

Director Jeffrey Bluestone reports acquisition of stock options and restricted stock units in Gilead Sciences, Inc.

Director Anthony Welters reports acquisition of restricted stock units and stock options in Gilead Sciences, Inc.

Director Javier Rodriguez reports acquisition of restricted stock units and stock options in Gilead Sciences.

Director Ted W. Love reports acquisition of Gilead Sciences stock and stock options, including 1,516 restricted stock units and options to purchase 6,809 shares, all vesting immediately.

Director Jacqueline K. Barton reports acquisition of restricted stock units and stock options in Gilead Sciences, Inc.

Deborah H. Telman, EVP, Corporate Affairs & GC of Gilead Sciences, reports transactions involving common stock and restricted stock units.

Gilead Sciences' Chief Financial Officer, Andrew Dickinson, sold 2,500 shares of common stock at a price of $106.4 per share on April 15, 2025, under a pre-arranged Rule 10b5-1 trading plan.

Gilead Sciences' Chief Financial Officer, Andrew Dickinson, executed a sale of 2,500 shares of common stock at a price of $110.53 per share, according to a Form 4 filing with the SEC.

Chief Commercial Officer Johanna Mercier reports the vesting of restricted stock units and acquisition of stock options in Gilead Sciences.

Gilead Sciences CEO Daniel O'Day reports the vesting and disposal of restricted stock units and the acquisition of stock options.

EVP Deborah H. Telman reports stock transactions including the vesting of restricted stock units and stock options, as well as adjustments for employee stock purchase plan acquisitions.

Andrew Dickinson, CFO of Gilead Sciences, reports transactions involving company stock, including the exercise of options and sale of shares, pursuant to a pre-arranged trading plan.

Sandra Patterson, SVP, Controllership at Gilead Sciences, reports the vesting and disposal of restricted stock units and shares acquired through the employee stock purchase plan.

Dietmar Berger, Chief Medical Officer of Gilead Sciences, reports the acquisition of restricted stock units and non-qualified stock options.

Gilead Sciences, Inc. reports acquiring 1,363,636 shares of Arcus Biosciences, Inc. at $11 per share, increasing its holdings to 31,424,760 shares.

Gilead Sciences' CFO, Andrew Dickinson, sold 2,500 shares of common stock at a price of $104.09 per share on February 18, 2025, according to a Form 4 filing with the SEC.

Andrew Dickinson, CFO of Gilead Sciences, exercised stock options and sold shares of common stock under a pre-arranged Rule 10b5-1 trading plan.

Sandra Patterson, SVP, Controllership at Gilead Sciences, reports the acquisition of 709 shares of common stock due to performance share award vesting.

EVP Deborah H. Telman reports acquisition of 12,371 shares of Gilead Sciences common stock following performance goal attainment.